Takeda Pharmaceutical Co ( (JP:4502) ) has provided an announcement.
Takeda Pharmaceutical Company reported its consolidated financial results for the fiscal year ended March 31, 2025, showing a 7.5% increase in revenue to 4,581,551 million JPY. Despite the revenue growth, the company experienced a 25% decline in net profit attributable to owners, amounting to 107,928 million JPY. The company’s financial position reflects a decrease in total assets and equity, while cash flow from operating activities improved significantly. The company has also announced a dividend increase and provided forecasts for the next fiscal year, indicating a slight revenue decline but a substantial increase in operating profit and net profit.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Company Limited is a global pharmaceutical company listed on multiple stock exchanges, including Tokyo and Nagoya. The company is primarily focused on developing and delivering innovative medicines in various therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases.
Average Trading Volume: 5,242,277
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen7003.9B
For an in-depth examination of 4502 stock, go to TipRanks’ Stock Analysis page.